MOLN

SEC filing MOLN Presents MP0712 Phase 1/2a Trial Updates at ASCO and SNMMI 2026, Dosing Patients with DLL3-Targeting Radio-DARPin Therapy

1d ago

SEC filing MOLN Reports $12B Revenue, $3.4B Net Income, Announces $20B Buyback

32d ago

SEC filing MOLN Elects Clare Fisher to Board, Approves $57.9M 2025 Loss Carryforward, Grants Discharge

48d ago

SEC filing MOLN Reports $93.1M Cash Runway to 2028, Initiates US Phase 1/2a DLL3 Radio-DARPin MP0712 Trial, Advances MSLN Candidate MP0726, Signs Eckert & Ziegler Radio-Isotope Deal

81d ago

SEC filing MOLN Reports $0 Revenue, $0 EPS, CHF 93.1M Cash, CHF 51.3M Operating Outflow, CHF 45-55M 2026 Expense Outlook

81d ago

News Molecular Partners GAAP EPS of -CHF1.65 beats by CHF0.32

81d ago

News L’Oreal Earnings: Solid Results Showcase Brand Strength and Operational Agility - Morningstar Canada

105d ago

News Self-driving truck startup Waabi is teaming up with Uber on robotaxis

125d ago

Scanner Unusual volume (14.5x average)

125d ago

News Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

153d ago

News Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

165d ago

News Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

166d ago